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Abstract: Autism spectrum disorders (ASDs) are heterogenous neurodevelopmental disorders characterized by impair-
ment in social, communication skills and stereotype behaviors. While autism may be uniquely human, there are behavioral 
characteristics in ASDs that can be mimicked using animal models. We used the BTBR T+tf/J mice that have been shown 
to exhibit autism-like behavioral phenotypes to 1). Evaluate cannabinoid-induced behavioral changes using forced swim 
test (FST) and spontaneous wheel running (SWR) activity and 2). Determine the behavioral and neurochemical changes 
after the administration of MDMA (20 mg/kg), methamphetamine (10 mg/kg) or MPTP (20 mg/kg). We found that the 
BTBR mice exhibited an enhanced basal spontaneous locomotor behavior in the SWR test and a reduced depressogenic 
profile. These responses appeared to be enhanced by the prototypic cannabinoid, 
9-THC. MDMA and MPTP at the doses 
used did not modify SWR behavior in the BTBR mice whereas MPTP reduced SWR activity in the control CB57BL/6J 
mice. In the hippocampus, striatum and frontal cortex, the levels of DA and 5-HT and their metabolites were differentially 
altered in the BTBR and C57BL/6J mice. Our data provides a basis for further studies in evaluating the role of the  
cannabinoid and monoaminergic systems in the etiology of ASDs.  
Keywords: Cannabinoid, Monoamines, 
9-THC, Psychostimulants, MPTP, Behavior, Autism, BTBR T+tf/J mice. 
INTRODUCTION 
  Autism is a behaviorally defined neurodevelopmental 
disorder characterized by impairments in social interaction 
and communication and repetitive/stereotyped behaviors [1, 
2]. The cause of autism is not completely understood and 
there is no effective cure. However, genetic and environ-
mental factors and the interaction between genes and envi-
ronment are known to play a role in Autism Spectrum Disor-
ders (ASDs) [3-7]. A common genetic variant on chromo-
some 5p14.1 was shown to associate with ASDs using ge-
nome-wide association studies [6] and there are currently a 
number of other autism susceptibility candidate genes 
(ASCG) that may be involved [7]. New thinking and hy-
pothesis have been generated to include epigenetic mecha-
nisms in ASDs [8, 9]. This is because of the complexity of 
ASDs and the understanding that alteration of gene function 
could be due to a polymorphism in DNA sequence or epige-
netic programming changes of genes in the interaction with 
environment without change of DNA sequences [10].  
  We recognize that the symptoms of ASDs are difficult to 
model in rodents because of the absence of verbal communi-
cation and the variability of symptoms. Nevertheless, a   
number of relevant behavioral and social changes have been 
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documented in transgenic mouse models of ASDs. Specifi-
cally mouse behavioral tests modeling some of the core 
symptoms of autism have now been established [11]. The 
goal of this study, was to use the mouse model to determine 
the role if any of the endocannabinoid system in autism. This 
was accomplished using the BTBR T+tf/J mice with autism-
like behavioral phenotypes. The behavioral, morphological 
and neurochemical alterations in this model will allow us to 
test our hypothesis about the causes of autism, and may serve 
as an index for the evaluation of proposed treatment strate-
gies in combination with other transgenic models. The ra-
tionale for this novel hypothesis arises from the discovery 
that the endocannabinoid system is one of the most abundant 
physiological control systems in animals and humans. This 
system is intricately involved with embryo development and 
growth with limitless interaction with most biological sys-
tems including the monoaminergic systems. The endocan-
nabinoid system consists of genes that encode cannabinoid 
receptors, endogenous ligands that activate these receptors 
and the enzymes that synthesize, degrade and perhaps re-
uptake the endocannabinoids [12]. While the endocannabi-
noid system is ubiquitous and interacts with most biological 
systems, the role it plays in ASDs is unknown. We recently 
observed that the basal level of CB2A gene expression in the 
BTBR T+tf/J mice was upregulated in the cerebellum com-
pared to control mice [13]. Therefore, we have begun studies 
to determine the behavioral effects of cannabinoid ligands in 
the BTBR mice in comparison to control groups. 210    Current Neuropharmacology, 2011, Vol. 9, No. 1  Onaivi et al. 
MATERIALS AND METHODS 
Animals 
  Adult male and female BTBR T+tf/J, C57BL/6J and 
129SI/SvImJ (S129) mouse strains were housed in individual 
cages with access to mouse chow 12 hr in the light and 12 hr 
in the dark. Experiments were conducted according to stan-
dard NIH guidelines and approved by Institutional Animal 
Care and Use Committee. 
Drugs 
  
9-THC was obtained from our collaborators in NIDA 
intra-mural program and it was made up in a 1:1:18 solution 
of alcohol: emulphur: saline. MDMA, methamphetamine, 
and MPTP were obtained from our FDA collaborators. Ani-
mals were injected intra-peritoneal (i.p) using 1.0 and 10 
mg/kg doses of 
9-THC and the control animals were in-
jected with the vehicle. The doses of MDMA (20 mg/kg), 
methamphetamine (10 mg/kg), MPTP (20 mg/kg) or d-
amphetamine (5 mg/kg) were used. In all experiments all 
drugs were injected in a volume of 1ml/kg. 
EXPERIMENTAL PROCEDURE 
Motor Function Test 
  Spontaneous wheel running monitors were used to access 
motor activity and function. The standard wheel running 
activity monitors measures the counts per revolution and was 
used to access the spontaneous wheel running behavior of 
naïve mice and following acute treatment with the test com-
pounds and corresponding vehicle used. The wheel running 
activity of the animals were monitored by the auto-counters, 
for 10 minutes during the assessment of spontaneous wheel 
running activity following specific drug pretreatment times. 
Data was obtained as total number of revolutions over the 10 
min evaluation period. The performance of the animals fol-
lowing the acute administration of the test compounds to the 
mouse strains were compared to their respective vehicle 
treated controls. 
Forced Swim Test 
  The forced swim test (FST) paradigm was used. It con-
sists of a glass cylinder (16 cm diameter and height 35 cm) 
filled to a depth 15 cm with water (23-25
oC). One glass cyl-
inder was used for each mouse and we tested six mice at a 
time using six glass cylinders and test observers. In this 
study a two-day swim test procedure was utilized first to 
access the basal performance of the different mouse strains. 
On the first day mice were placed in the glass cylinder with 
water to the specified depth, and all animals were exposed 
for 15-min pre-swim test prior to the 5-min forced swim test 
on day 2. Fresh water was introduced prior to each test. The 
test sessions were recorded by trained observers for consis-
tent data recording. The observer used stop watches and 
counters to record immobility times and counts respectively. 
The data recorded during the 5-min test session were the 
times the animals were immobile and also the number of 
immobility counts during the test session. Similar data was 
obtained for the vehicle treated naïve control animals. Dur-
ing the test session the duration of immobility was defined 
by the animal’s stationary position, and only made the mini-
mal movements necessary to keep the head above water. 
Neurochemical Analysis of Dopamine (DA) and   
Serotonin (5HT) and their Metabolites in Selected Brain 
Areas 
  Prior to preparation of animals for selected brain region 
dissection for neurochemical analysis, animals were sched-
uled for three saline or three drug injections that were given 
about 8 hrs apart for one day only. Mice in the different 
groups were injected with saline (n = 10) or these test com-
pounds (n = 10/per group): methamphetamine (10 mg/g); 
MDMA (20 mg/kg) or MPTP (20 mg/kg). After the comple-
tion of drug or vehicle administration, mice were housed one 
per cage for two days before the animals were sacrificed two 
days later, and the striatum, frontal cortex and hippocampus 
were dissected and frozen at -80
oC. All frozen samples were 
shipped to the FDA for the neurochemical analysis. Briefly, 
tissues from the different groups were prepared for high per-
formance liquid chromatography (HPLC) combined with 
electrochemical detection to determine dopamine (DA), 3, 4-
dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
(HVA), serotonin (5HT) and 5-hydroxyindole acetic acid 
(5HIAA). 
CANNABINOID GENOMIC ANALYSIS IN BTBR 
MICE 
  In a previous study Liu et al., 2009, [13], during the 
analysis of CB2-R gene expression in different brain regions 
of C57BL/6 mice treated with the mixed cannabinoid agonist 
WIN55212-2 (2mg/kg) for 7 days, we also analyzed CB2-
gene expression in non-injected BTBR mice. This was ac-
complished by the analysis of CB2A and CB2B gene expres-
sion in brain regions, testis and the spleen. Briefly, RNA was 
isolated using TRIzol reagent and cDNA synthesized using 
SuperScript III first strand synthesis system for RT-PCR 
(Invitrogen, Carlsbad, CA). The expression of CB2A and 
CB2B genes were compared by TaqMan real-time PCR with 
an ABI PRISM 7900 HT Sequence Detection System, using 
custom designed Fam-labeled MGB probes and primers for 
CB2A and CB2B (Applied Biosystems, Foster City, CA). 
The custom-designed mouse beta-actin Fam-labeled MGB 
probe was used for normalization [13]. 
Statistical Analysis 
  Prism-3 program, version 3.02 (Graphpad Software, Inc., 
San Diego, CA, USA) was used for statistical analyses, in-
cluding  t-tests and analysis of variance (ANOVA). Data 
from motor function and forced swim tests were subjected to 
analysis of variance for multiple comparisons followed by 
Turkey’s test where appropriate. For CB1 and CB2 gene 
expression analysis, unpaired t-test was used. The accepted 
level of significance is P < 0.05. 
RESULTS 
Effects of 
9-THC, Psychostimulants and Disruption of 
Monoaminergic System by MPTP on Motor Activity in 
the Mouse Model of ASD 
  The naïve untreated BTBR mice exhibited an enhanced 
basal locomotor activity as recorded in the spontaneous 
wheel running test. The BTBR males had slightly higher 
activity than the females and the motor activity of the males 
of the C57BL/6J were significantly lower (p<0.05, N = 10) Consequences of Cannabinoid and Monoaminergic System Disruption  Current Neuropharmacology, 2011, Vol. 9, No. 1    211 
than the activity of the BTBR males as shown in Fig. (1A). 
The effects of d-amphetamine treatment in the three mouse 
strains varied, with the S129 mouse showing significant lo-
comotor activation compared to both BTBR and C57BL/6J 
mice as shown in Fig. (1B). A similar response of male and 
female mice in motor activity was recorded following the 
acute treatment of BTBR and C57BL/6J, with metham-
phetamine and MDMA (Fig. (1C)). The motor activity of 
C57BL/6J male mice was significantly reduced compared to 
those of the BTBR mice after treatment with the dopaminer-
gic neurotoxin MPTP as shown in Fig. (1C). However, the 
motor activity of BTBR mice when compared to those of 
C57BL/6J and S129 mice were significantly reduced and 
more sensitive to the higher dose of 10 mg/kg 
9-THC used 
in this study as shown in Fig. (2C). At the doses used in this 
study  
9-THC actually enhanced motor activity in the 
C57BL/6J and S129 mice which were the control back-
ground mice for the BTBR animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The effects of psychostimulants (d-amphetamine, Methamphetamine and MDMA), and disruption of monoaminergic system by the 
neurotoxin (MPTP), in a mouse model of autism spectrum disorders. Panel A shows the basal motor activity of male and female BTBR and 
C57BL/J mice in the spontaneous wheel running (SWR) monitors; panel B is the effect of acute 10 min treatment with d-amphetamine (5.0 
mg/kg) on the performance of male BTBR and the male controls, S129 and C57BL/6J mice. Panel C shows the effects of acute administra-
tion of methamphetamine (10 mg/kg), MDMA (20.0 mg/kg) and MPTP (20 mg/kg) in both male and female BTBR and C57BL/6J mice in 
comparison to their respective controls. The duration of the wheel running behavior was accessed over a 10 min period in all animals tested. 
* or ¶ represents statistical significance at p<0.05 as compared to the same gender. 
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Behavioral Effects of BTBR, C57BL/6J and S129   
Mice in the Forced Swim Test after Treatment with a   
Cannabinoid, 
9-THC: 
  The naïve BTBR mice demonstrated reduced immobility 
time and increased immobility count when compared to 
C57BL/6J and S129 mice in the FST, as shown in Fig. (2A). 
Surprisingly, in the FST, 
9-THC at the doses used did not 
modify the immobility time and counts of the BTBR mice 
when compared to the C57BL/6J and S129 mice as shown in 
Fig. (2B). 
Neurochemical Determination of DA and 5HT Levels 
and their Metabolites after Treatment with 
Methamphetamine, MDMA and MPTP 
  The levels of dopamine, serotonin and their metabolites 
were analyzed in the striatum, frontal cortex and the hippo-
campus after the treatment of different strains of mice with 
methamphetamine, MDMA and MPTP. Data on striatal DA 
and 5HT levels and frontal cortex 5HT levels are presented 
in Fig. (3). In this preliminary neurochemical analysis of 
DA, 5HT and their metabolite levels in the striatum, frontal 
cortex and hippocampus after the drug treatments, the levels 
of these monoamines and their metabolites were differen-
tially altered in the BTBR and C57BL/6J mice used, see Fig. 
(3). The variable levels of monoamines made it difficult to 
define a specific association of these changes with the under-
lying features in the mouse model of ASDs. There are how-
ever some striking observations that can be gleaned from the 
effects of the doses used in drug treatments and the analyzed 
comparative striatal data between BTBR and C57BL/6J 
mice: Methamphetamine lowered BTBR DA levels relative 
to controls with no effect on C57BL/6J DA levels whereas 
MPTP had no effect on DA levels in BTBR mice relative to 
their controls, but lowered C57BL/6J DA levels. On the 
other hand MDMA had little on no significant effect on ei-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Behavioral effects of BTBR, C57BL/6J and S129 mouse strains in the FST. Panel A shows the basal levels of performance  
indicated by the time and number of immobility by the three mouse strains in the forced swim test model. Panel B is time and number  
of immobility after acute treatment of the mouse strains with 
9-THC (1 and 10 mg/kg) in comparison to vehicle treated controls. Panel C 
shows the influence of acute treatment of the mouse strains with 
9-THC (1 and 10 mg/kg) in the spontaneous wheel running activity  
monitors. * or + represents statistical significance at p<0.05 with strains and drug treatment in the behavioral measures. Consequences of Cannabinoid and Monoaminergic System Disruption  Current Neuropharmacology, 2011, Vol. 9, No. 1    213 
ther BTBR or C57BL/6J DA levels in comparison to their 
respective controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Neurochemical analysis of dopamine (DA) and serotonin 
(5HT) levels in striatum and frontal cortex in BTBR and C57BL/6J 
male and female mice following a single day three times admini-
stration of either saline, methamphetamine (10 mg/kg), MDMA (20 
mg/kg) or MPTP (20 mg/kg). Regional brain areas were dissected 2 
days later. Since there were no significant sex differences the data 
was collapsed on the variable sex. Panel A is the striatal dopamine 
level in BTBR relative to C57BL/6J mice. Panel B is the frontal 
cortex dopamine level in the two strains of mice. Panel C is the 
striatal serotonin level. *Represents statistical significance at 
p<0.05 using a least squares means analysis. Significance tests were 
performed between the two strains of mice for each of the treat-
ments independently. 
Cannabinoid CB2A Gene Expression is Upregulated in 
BTBR Mice 
  We have previously shown that naive BTBR mice   
that have been reported to have autism-like behavioral phe-
notypes have an upregulated higher levels of CB2A gene 
expression in the cerebellum without treatment with   
cannabinoids. This upregulation occurred usually only after 
sub-acute treatment with a mixed cannabinoid agonist, 
WIN55212-2 in the C57BL/6J mice [13]. However, no sig-
nificant changes were observed in other brain regions includ-
ing frontal cortex and striatum - brain areas evaluated in the 
current study and the hypothalamus (data not shown). The 
expression level of CB2B in the mouse brain is lower than 
CB2A and the mRNA levels could not be reliably measured 
by TaqMan assay (data not shown). 
DISCUSSION 
  While autism may be uniquely human, we have investi-
gated the consequences of cannabinoid and monoaminergic 
system disruption in the BTBR T+tf/J mice that have been 
shown to exhibit autism-like behavioral phenotypes. We 
report that the BTBR mice exhibited an enhanced basal 
spontaneous locomotor behavior in the spontaneous wheel 
running (SWR) test, a measure of locomotor activity, that 
was reduced by the prototypic cannabinoid, 
9-THC. In ad-
dition, this enhanced spontaneous wheel running behavior 
was sexually dimorphic as the motor activity in the naïve 
male BTBR mice was significantly higher than those of the 
naïve male C57BL/6J mice without significant alteration in 
the female mice. Furthermore, the doses of the psychostimu-
lants, d-amphetamine, methamphetamine and MDMA used 
in this study did not modify the SWR behavior in the BTBR 
mice whereas MPTP reduced SWR activity in the control 
CB57BL/6J mice. One characteristic of ASDs is stereotype 
behavior characterized by high levels of repetitive self-
grooming behavior that has recently been shown to be re-
duced in the BTBR mice by methyl-6-phenylethynl-pyridine 
(MPEP) – an mGluR5 antagonist [14]. It is tempting to sug-
gest the evaluation of 
9-THC or other cannabinoids with 
reduced psychoactivity in irritability, tantrums and self-
injurious behavior associated with autistic individuals. This 
is because at the low doses used in this study, only the 
BTBR mice were sensitive to motor depressant effects of 
9-
THC when compared to those of C57BL/6J and S129 mice. 
This hypothesis is further supported by our data showing   
that the BTBR mice were also insensitive to the locomotor 
activation induced by psychostimulants and the neurotoxic 
effects of MPTP when compared to those of C57BL/6J and 
S129 mice. 
  An unusual behavioral phenotype characterized by exag-
gerated responses to stress in the BTBR mouse has been 
demonstrated [15]. The study showed that the BTBR mice had 
increased levels of the stress hormone corticosterone follow-
ing tail suspension, and a heightened anxiety response in the 
plus-maze test, when compared to C57BL/6J mice [15]. In 
our current study, there were marked strain differences in 
immobility times and counts in the FST model of depression 
and BTBR mice displayed a reduced immobility time and an 
enhanced immobility count compared to the control 
C57BL/6J and S129 mice. Curiously however, 
9-THC at 
the doses used in this study did not modify the immobility 
time and counts in BTBR mice when compared to the 
C57BL/6J and S129 mice whose immobility times and counts 
were differentially modified dose dependently by 
9-THC. 214    Current Neuropharmacology, 2011, Vol. 9, No. 1  Onaivi et al. 
  The cause of autism is unknown, but there has been much 
progress and new knowledge with the environment, epige-
netics and genetic factors all playing some role in the etiol-
ogy of ASDs. For example multiple gene variants and ge-
nome-wide copy number variations have been reported in 
children with ASDs, but not in healthy controls [16]. Data 
from comparative genomics of autism and schizophrenia 
support the hypothesis that autism and schizophrenia repre-
sent diametric conditions with regard to their genomic un-
derpinnings and phenotypic manifestations [16]. Our data 
indicating that the BTBR mice have an abnormal regulation 
of DA functioning with an upregulated CB2A gene expres-
sion in naïve BTBR mouse of ASDs [13], and our finding 
indicating an increased risk of schizophrenia in patients with 
low CB2 receptor function [17], is in agreement with the 
hypothesis that autism and schizophrenia represent diametric 
conditions [16]. Moreover, more research needs to be done 
to understand the nature of the neurochemical changes re-
corded in our preliminary study in the hippocampus, striatum 
and frontal cortex, where the levels of DA and 5-HT and 
their metabolites were differentially altered in the BTBR and 
C57BL/6J mice. Thus our data provides a basis for further 
studies in evaluating the role of the cannabinoid and mono-
aminergic systems in the etiology of ASDs and whether the 
BTBR mice can model both schizophrenia and ASDs.  
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